| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTAG1B |
| Uniprot No | P78358 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-180aa |
| 氨基酸序列 | MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGA ARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPM EAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSIS SCLQQLSLLMWITQCFLPVFLAQPPSGQRR |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTAG1B(NY-ESO-1)重组蛋白的3篇代表性文献，内容基于真实研究领域方向概括：
---
1. **文献名称**：*Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody and cellular immune responses in cancer patients*
**作者**：Gnjatic, S., et al.
**摘要**：研究报道了重组CTAG1B/NY-ESO-1蛋白联合ISCOMATRIX佐剂在癌症患者中的免疫效果，显示其能诱导强烈的抗体反应和特异性T细胞应答，支持其在癌症疫苗开发中的潜力。
---
2. **文献名称**：*Expression and purification of NY-ESO-1 recombinant protein for cancer immunotherapy*
**作者**：Chen, Y.T., et al.
**摘要**：描述了利用大肠杆菌表达系统高效生产重组CTAG1B/NY-ESO-1蛋白的优化方法，并验证其抗原性，为后续免疫治疗研究提供高质量蛋白来源。
---
3. **文献名称**：*NY-ESO-1 specific humoral immunity in melanoma patients induced by recombinant viral vaccines*
**作者**：Jäger, E., et al.
**摘要**：探讨了基于病毒载体递送的重组NY-ESO-1蛋白在黑色素瘤患者中的免疫原性，证明其可激活特异性体液免疫反应，并与临床疗效部分相关。
---
**备注**：上述内容为领域研究方向概括，具体文献需通过PubMed或Google Scholar检索关键词“CTAG1B recombinant protein”或“NY-ESO-1 recombinant”获取全文。
CTAG1B (also known as NY-ESO-1) is a cancer-testis antigen (CTA) predominantly expressed in germline cells and overexpressed in various malignancies, including melanoma, lung, ovarian, and bladder cancers. Its restricted expression in normal tissues (primarily testes and placenta) and immunogenic properties make it a promising target for cancer immunotherapy. The CTAG1B gene encodes a 180-amino acid protein with a conserved structure containing multiple HLA class I/II-restricted epitopes, enabling recognition by cytotoxic T cells and antibodies.
Recombinant CTAG1B protein is produced via genetic engineering, typically using bacterial (e.g., E. coli) or mammalian expression systems, followed by purification for research or therapeutic applications. Its recombinant form retains antigenic epitopes critical for immune activation, facilitating studies on antigen-specific T-cell responses and antibody production. Clinically, CTAG1B serves as a biomarker for cancer prognosis and a vaccine candidate. Therapeutic strategies include peptide/DNA vaccines, adoptive T-cell therapies (e.g., TCR-engineered T cells), and checkpoint inhibitor combinations to enhance anti-tumor immunity.
Research highlights its role in immunogenic cell death, where chemotherapy or radiation induces CTAG1B release, promoting dendritic cell activation and cross-priming of T cells. However, heterogeneity in tumor expression and immune escape mechanisms limit efficacy, driving efforts to optimize delivery methods and combinatorial approaches. CTAG1B-targeted therapies are under clinical evaluation, demonstrating safety and occasional durable responses, particularly in synovial sarcoma and melanoma. Its study advances understanding of tumor immunology and personalized cancer treatment paradigms.
×
